After J&J’s Janssen succeeded in obtaining a US injunction preventing Accord and Bio-Thera from launching their FDA-approved ...

A UK ruling that Eli Lilly breached industry Code of Practice for a press release and new Australian guidance on media ...

California's top court refused to hold Gilead liable for delaying a safer HIV drug to protect its franchise – a win for ...

Now that we are trying to complete and devise some efforts about how to follow those requirements, it's sometimes being ...

The FDA selected three more technologies for its READI-Home Innovation Challenge, including home blood collection from Becton ...

Amid ongoing geopolitical complexities and “profound transformations” affecting the pharmaceutical industry, French ...

The Vaccines and Related Biological Products Advisory Committee recommended the same influenza A and B strains found in the ...

But if the mandatory Most Favored Nation payment model was always meant primarily as a stick to coerce manufacturers into ...

Manufacturers could accede to Trump Administration pressure and agree to MFN deals that include participating in the GENEROUS ...

The company said it plans to file for approval of the azacitidine/cedazuridine combination pill in myelodysplastic syndromes ...

IL-4 and TSLP with Pfizer’s trispecific antibody, which the firm has moved into Phase III studies in two indications, ...

TL1A inhibition is a competitive area of R&D. Merck has the lead in IBD with tulisokibart, and new Phase II data support a ...